dostęp otwarty
W parze skuteczniej i bezpieczniej, czyli kiedy ezetimib staje się nieocenionym partnerem w terapii dyslipidemii
dostęp otwarty
Streszczenie
Streszczenie
Słowa kluczowe
dyslipidemia, ezetimib, statyna, terapia skojarzona


Tytuł
W parze skuteczniej i bezpieczniej, czyli kiedy ezetimib staje się nieocenionym partnerem w terapii dyslipidemii
Czasopismo
Numer
Strony
1-9
Rekord bibliograficzny
Choroby Serca i Naczyń 2018;15(1):1-9.
Słowa kluczowe
dyslipidemia
ezetimib
statyna
terapia skojarzona
Autorzy
Marcin Barylski


- Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213–223.
- Pikto-Pietkiewicz W, Pasierski T. Ezetymib — inhibitor wchłaniania cholesterolu. Kardiol Pol. 2006; 64: 1434–1441.
- Broncel M. Miejsce ezetymibu we współczesnej terapii hipolipemizującej. KOF. 2010; 3: 211–218.
- Altmann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004; 303(5661): 1201–1204.
- Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2007; 3(3): 441–450.
- Knopp RH, Dujovne CA, Le Beaut A, et al. Ezetimbe Study Group. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003; 57(5): 363–368.
- Nakagami H, Osako MK, Takami Y, et al. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis. 2009; 203(1): 51–58.
- Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005; 111(18): 2356–2363.
- Gagné C, Bays HE, Weiss SR, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002; 90(10): 1084–1091.
- Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002; 40(12): 2125–2134.
- Bardini G, Giorda CB, Pontiroli AE, et al. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010; 9: 20.
- Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005; 80(5): 587–595.
- Reckless JPD, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008; 62(4): 539–554.
- Ballantyne CM, Weiss R, Moccetti T, et al. EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007; 99(5): 673–680.
- Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract. 2009; 63(4): 547–559.
- Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009; 103(12): 1694–1702.
- Rossebø AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol. 2007; 99(7): 970–973.
- McCormack T, Harvey P, Gaunt R, et al. IN-PRACTICE study. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract. 2010; 64(8): 1052–1061.
- Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011; 108(4): 523–530.
- Ballantyne CM, Hoogeveen RC, Raya JL, et al. GRAVITY Study Investigators. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014; 232(1): 86–93.
- Tsujita K, Sugiyama S, Sumida H, et al. PRECISE–IVUS Investigators. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention. J Am Coll Cardiol. 2015; 66(5): 495–507.
- Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010; 160(5): 785–794.e10.
- Farnier M, Freeman MW, Macdonell G, et al. Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005; 26(9): 897–905.
- Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
- Charakterystyka Produktu Leczniczego Ezoleta, 10 mg, tabletki, 03.02.2017.
- van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008; 52(17): 1421–1429.
- Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol. 2010; 105(5): 656–663.
- Catapano AL, Graham I, Backer GDe, et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.